Active Ingredient History
Pioglitazone (brand name Actos) is a prescription drug of the thiazolidinedione class with hypoglycemic action used in the treatment of type 2 diabetes. Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. It modulates the transcription of the genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues, decreases gluconeogenesis in the liver, and reduces the quantity of glucose and glycated hemoglobin in the bloodstream. Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin, or insulin. Pioglitazone cannot be used in patients with a known hypersensitivity to pioglitazone, other thiazolidinediones or any of components of its pharmaceutical forms. It is ineffective and possibly harmful to diabetes mellitus type 1 and diabetic ketoacidosis. Pioglitazone can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on pioglitazone had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adrenoleukodystrophy (approved 1999)
Diabetes Mellitus, Type 2 (approved 1999)
Adrenoleukodystrophy (Phase 2)
Airway Management (Phase 2)
Alcohol Drinking (Phase 2)
Alcoholism (Phase 2)
Alcohol-Related Disorders (Phase 2)
Alzheimer Disease (Phase 3)
Amyotrophic Lateral Sclerosis (Phase 2)
Androgens (Phase 3)
Anemia (Phase 1)
Angina Pectoris (Phase 4)
Arterial Occlusive Diseases (Phase 2/Phase 3)
Arthritis, Rheumatoid (Phase 3)
Ascites (Phase 4)
Asthma (Phase 4)
Astrocytoma (Phase 1)
Ataxia Telangiectasia (Phase 4)
Atherosclerosis (Phase 4)
Autism Spectrum Disorder (Phase 2)
Autoimmune Diseases (Phase 1)
Bipolar Disorder (Phase 4)
Blood Platelets (Phase 2)
Body Weight (Phase 4)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Bronchopulmonary Dysplasia (Phase 2)
Burns (Phase 2/Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Cardiovascular Diseases (Phase 4)
Cerebral Hemorrhage (Phase 2)
Cocaine-Related Disorders (Phase 2)
Cognitive Dysfunction (Phase 2)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Coronary Restenosis (Phase 3)
Coronary Stenosis (Phase 4)
Coronavirus Infections (Phase 4)
COVID-19 (Phase 4)
Cystic Fibrosis (Phase 1)
Depressive Disorder, Major (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drug Evaluation (Phase 4)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 1)
Dyslipidemias (Phase 3)
Endocrine System Diseases (Phase 3)
Endometriosis (Phase 2/Phase 3)
Endothelium (Phase 4)
Fat Body (Phase 2)
Fatty Liver (Phase 4)
Fibrosis (Phase 4)
Friedreich Ataxia (Phase 3)
Gastroparesis (Early Phase 1)
Glioblastoma (Phase 1)
Glucose Intolerance (Phase 4)
Glucose Metabolism Disorders (Phase 4)
Gout (Phase 4)
Granulomatous Disease, Chronic (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 4)
Hearing Loss (Phase 3)
Heart Diseases (Phase 3)
Heart Ventricles (Phase 4)
Hepatitis (Phase 2)
Hepatitis C (Phase 4)
Hepatitis C, Chronic (Phase 4)
Heroin Dependence (Phase 1/Phase 2)
HIV (Phase 4)
HIV-Associated Lipodystrophy Syndrome (Phase 3)
HIV Infections (Phase 4)
Hyperandrogenism (Phase 1/Phase 2)
Hypercholesterolemia (Phase 3)
Hyperglycemia (Phase 1/Phase 2)
Hypertension (Phase 4)
Hypertension, Portal (Phase 4)
Hypertension, Pulmonary (Phase 2)
Hypoglycemic Agents (Phase 3)
Infertility (Early Phase 1)
Infertility, Female (Early Phase 1)
Inflammation (Phase 4)
Insulin Resistance (Phase 4)
Intermittent Claudication (Phase 2/Phase 3)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukoplakia, Oral (Phase 2)
Lipodystrophy (Phase 4)
Liposarcoma (Phase 2)
Liposarcoma, Myxoid (Phase 2)
Livedoid Vasculopathy (Phase 2)
Liver (Phase 4)
Liver Diseases (Phase 4)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Systemic (Phase 4)
Meningioma (Phase 1)
Menstruation Disturbances (Phase 1/Phase 2)
Metabolic Diseases (Phase 3)
Metabolic Syndrome (Phase 4)
Metabolism (Phase 4)
Multiple Myeloma (Phase 1/Phase 2)
Multiple Sclerosis (Phase 1/Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 1)
Muscle Fatigue (Phase 2)
Muscular Diseases (Phase 1)
Musculoskeletal Diseases (Phase 1)
Myocardial Infarction (Phase 3)
Myositis (Phase 1)
Myositis, Inclusion Body (Phase 1)
Neoplasms (Phase 2)
Nervous System Diseases (Phase 1)
Neuromuscular Diseases (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity (Phase 4)
Opioid-Related Disorders (Phase 2)
Oropharyngeal Neoplasms (Phase 2)
Osteoporosis (Phase 4)
Overweight (Phase 1)
Oxidative Stress (Phase 4)
Pancreatic Neoplasms (Phase 2)
Pancreatitis, Chronic (Phase 2)
Parkinson Disease (Phase 2)
Percutaneous Coronary Intervention (Phase 4)
Peripheral Arterial Disease (Early Phase 1)
Pharmacokinetics (Phase 1)
Pharmacology (Phase 4)
Pioglitazone (Phase 1)
Pneumonia (Early Phase 1)
Polycystic Kidney Diseases (Phase 2)
Polycystic Ovary Syndrome (Phase 4)
Prediabetic State (Phase 4)
Pressure Ulcer (Phase 2)
Prostatic Neoplasms (Phase 3)
Proteinuria (Phase 3)
Psoriasis (Phase 2)
Psychological Distress (Phase 2)
Renal Insufficiency, Chronic (Phase 4)
Risk Reduction Behavior (Phase 3)
Sepsis (Phase 1/Phase 2)
Shock, Septic (Phase 1/Phase 2)
Sleep Apnea, Obstructive (Phase 4)
Spinal Cord Injuries (Phase 2)
Steatitis (Phase 4)
Stroke (Phase 3)
Thyroid Neoplasms (Phase 2)
Tobacco Use Disorder (Phase 1/Phase 2)
Vascular Diseases (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
